IW-9179 is an investigational guanylate cyclase-C (GC-C) agonist. GC-C is a receptor found mainly on the surface of the intestine and is recognized to be a potential therapeutic target in certain gastrointestinal diseases. Although GC-C is found throughout the gastrointestinal tract, IW-9179 is designed to act primarily in the upper gastrointestinal tract. Ironwood is investigating IW-9179 for the treatment of gastroparesis, with an initial focus on diabetic gastroparesis, and for functional dyspepsia, both of which are upper gastrointestinal disorders characterized by upper abdominal pain, bloating, fullness and nausea, among other symptoms. Data from a Phase I study indicate IW-9179 is minimally absorbed and generally well-tolerated, and initial data from a 10-patient Phase IIa study in which enrollment was limited by stringent inclusion criteria suggest IW-9179 may have applicability in patients with functional dyspepsia. Ironwood is working with gastrointestinal experts and regulatory authorities to define a path forward for IW-9179 in functional dyspepsia. The most common adverse event in both studies was diarrhea. Ironwood has an issued composition of matter patent in the U.S. covering IW-9179, which expires in 2031, and additional patents are allowed and pending in the U.S. and throughout the world.
|Cas Registry Number||1667762-62-0|
|New Molecular Entity||Yes|
|Mechanism Of Action||Guanylate cyclase C agonist|
|Who Atc Codes||A03 (Drugs for Functional Gastrointestinal Disorders)|
|Ephmra Codes||A3 (Functional Gastro-Intestinal Disorder Drugs)|
|Indication||Diabetic Gastroparesis, Dyspepsia, Functional Gastrointestinal Disorders|